犬心脏病：听杂音只是开始，咳嗽和"夜里喘"才是分期信号 · MetaPaw 宠物知识站

🐾MetaPaw 宠物知识站

收藏登录 / 注册

犬心脏病：听杂音只是开始，咳嗽和"夜里喘"才是分期信号 · MetaPaw 宠物知识站

在家怎么处理：数呼吸、控盐、按时复查

第一步：家庭最重要的指标——静息呼吸频率

怎么数：在它熟睡或安静趴着时，看胸腹起伏一次算 1 次，数 30 秒 × 2（不要刚运动完数）。
正常值：多数犬静息 < 30 次/分。
警戒线：持续 > 35～40 次/分往往提示肺淤血/胸水加重，应尽快联系兽医。
怎么做：每天固定时间数 1～2 次并记在表格里；趋势比单次数值重要，连续 3 天上升就要警惕。
同时观察：咳嗽（尤其夜间/清晨）、运动耐受下降、舌色发紫、突然无力或晕厥。

第二步：家庭照护的具体操作

严格控盐：不给火腿、香肠、咸味零食、餐桌剩菜；选择兽医认可的低钠饮食方案。
运动管理：改成短时、低速、平坦路线的散步（每次 10～15 分钟，看耐受调整）；避免高温高湿天气外出、避免剧烈兴奋。
体重与肌肉：过瘦（心源性恶病质）和过胖都加重负担；保持稳定体重与温和活动。
环境降温：心脏病犬对热极不耐受，夏天空调、避免中午外出、随时有水。
减少应激：家里保持安静规律，避免大吵大闹与突然剧烈兴奋。

第三步：用药是长期工程

不能漏服、不能自行停药：心药（如利尿剂、匹莫苯丹等）剂量与时间是按体重与病情精算的，漏服或自行减量会迅速恶化。可设置手机闹钟并用分药盒。
观察副作用：利尿剂会让喝水排尿增多（正常），但若出现虚弱、呕吐、食欲废绝、呼吸突然加快要立刻联系医生（可能是电解质紊乱或肾功能变化）。
复查节点：按医嘱定期复查 X 光/心超/肾功能与电解质，把每次结果抄在一起对比。

多久必须急诊

静息呼吸持续 > 40 次/分、张口呼吸、舌色发紫、突然昏倒、咳出粉红色泡沫——这些是心衰急症表现，立刻送医；
咳嗽频率明显上升、夜间无法平卧休息，也应在 24 小时内就诊。

照着做清单（0/15）

第一步：家庭最重要的指标——静息呼吸频率

第二步：家庭照护的具体操作

第三步：用药是长期工程

多久必须急诊

勾选状态只保存在你自己的浏览器里，换设备不会同步；清单是家庭照护参考，不能替代兽医诊断。

2

European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers

Wess G, Domenech O, Dukes-McEwan J, Häggström J 等 · Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology · 2017

👉 DCM 品种筛查方案，支撑易感犬定期超声/心电图监测。

PubMed 原文 ↗Europe PMC 镜像 ↗DOI 全文 ↗按标题检索 ↗DOI 10.1016/j.jvc.2017.08.006

展开原文摘要（英文，1654 字）

Dilated cardiomyopathy (DCM) is the most common cardiac disease in large breed dogs and is inherited in Doberman Pinschers with a high prevalence (58%). The European Society for Veterinary Cardiology convened a task force to formulate screening guidelines for DCM in Dobermans. Screening for occult DCM in Dobermans should start at three years of age and use both Holter monitoring and echocardiography. Yearly screening over the life of the dog is recommended, as a one-time screening is not sufficient to rule out future development of DCM. The preferred echocardiographic method is the measurement of the left ventricular volume by Simpson's method of discs (SMOD). Less than 50 single ventricular premature complexes (VPCs) in 24 h are considered to be normal in Dobermans, although detection of any number of VPCs is cause for concern. Greater than 300 VPCs in 24 h or two subsequent recordings within a year showing between 50 and 300 VPCs in 24 h is considered diagnostic of occult DCM in Dobermans regardless of the concurrent echocardiographic findings. The guidelines also provide recommendations concerning ancillary tests, that are not included in the standard screening protocol, but which may have some utility when recommended tests are not available or financially untenable on an annual basis. These tests include assay of cardiac biomarkers (Troponin I and N-Terminal pro-B-type Natriuretic Peptide) as well as a 5-min resting electrocardiogram (ECG). The current guidelines should help to establish an early diagnosis of DCM in Dobermans. Crown Copyright © 2017. Published by Elsevier B.V. All rights reserved.

3

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial

Boswood A, Häggström J, Gordon SG, Wess G 等 · Journal of veterinary internal medicine · 2016

👉 随机对照试验：临床前干预延后心衰发生，支撑"杂音期就做专科评估"。

PubMed 原文 ↗Europe PMC 镜像 ↗DOI 全文 ↗按标题检索 ↗DOI 10.1111/jvim.14586

展开原文摘要（英文，1839 字）

Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown. Administration of pimobendan (0.4-0.6 mg/kg/d in divided doses) to dogs with increased heart size secondary to preclinical MMVD, not receiving other cardiovascular medications, will delay the onset of signs of CHF, cardiac-related death, or euthanasia. 360 client-owned dogs with MMVD with left atrial-to-aortic ratio ≥1.6, normalized left ventricular internal diameter in diastole ≥1.7, and vertebral heart sum >10.5. Prospective, randomized, placebo-controlled, blinded, multicenter clinical trial. Primary outcome variable was time to a composite of the onset of CHF, cardiac-related death, or euthanasia. Median time to primary endpoint was 1228 days (95% CI: 856-NA) in the pimobendan group and 766 days (95% CI: 667-875) in the placebo group (P = .0038). Hazard ratio for the pimobendan group was 0.64 (95% CI: 0.47-0.87) compared with the placebo group. The benefit persisted after adjustment for other variables. Adverse events were not different between treatment groups. Dogs in the pimobendan group lived longer (median survival time was 1059 days (95% CI: 952-NA) in the pimobendan group and 902 days (95% CI: 747-1061) in the placebo group) (P = .012). Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated. Prolongation of preclinical period by approximately 15 months represents substantial clinical benefit. Copyright © 2016 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.